Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

Evan Y. Yu,José Manuel Rodríguez,Gwenaelle Gravis,Brigitte Laguerre,Jose Angel Arranz Arija,Stéphane Oudard,Peter C.C. Fong,Michael Paul Kolinsky,Marinela Augustin,Tilman Todenhöfer,Audrey E. Kam,Howard Gurney,Ali Tafreshi,Margitta Retz,William R. Berry,Nataliya Mar,Haiyan Wu,Ping Qiu,Charles Schloss,Johann S. de Bono

Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

2020

5544Background: Pembro + olaparib has shown antitumor activity and acceptable safety in docetaxel-pretreated pts with mCRPC enrolled in cohort A of the phase I/II KEYNOTE-365 study (NCT02861573). U...

Keywords:

Oncology
Olaparib
Internal medicine
Biomarker (medicine)
Prostate cancer
in patient
Cohort
castration resistant
Pathology
Pembrolizumab
Docetaxel
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations